We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN

Read time: Less than a minute

Signet Laboratories, Inc. has announced the availability of two monoclonal antibodies L1 clone 14.10 and PTEN clone 6H2.1

The mouse monoclonal anti-L1 clone 14.10 recognizes the L1 protein (CD171), a transmembrane protein that belongs to the immunoglobulin supergene family.

Data indicate that L1 may be overexpressed in a variety of carcinomas. Studies have implicated L1 as a marker of unfavorable prognosis in a variety of malignancies.

Clone 6H2.1 recognizes PTEN (phosphatase and tensin homolog), a tumor suppressor protein that is encoded by a gene located on chromosome 10. PTEN mutations have been observed in a wide range of cancers.

The addition of L1 and PTEN complements Signet's current product offerings for cancer research. Signet's product portfolio includes markers such as D2- 40, Cyclin D1, Cyclin E, HE4 and Hepsin.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.